COVID-19

Future-Proofed Pandemic Treatments and Protecting the Immunocompromised Population

Future-Proofed Pandemic Treatments and Protecting the Immunocompromised Population

Eugene Chan, MD, MPH, is the chairman and co-founder of Abpro, a company working to advance monoclonal antibodies to be used to treat Covid-19. He joins Neal to discuss the importance of protecting the immunocompromised population amidst mutating Covid-19 variants and shares the latest on the development of Abpro’s infectious disease antibody treatment that has demonstrated best-in-class efficacy against the multiple Omicron variants. For more information, visit: www.abpro.com.

Frequently Asked Questions

What is the main topic discussed in this episode of Health Professional Radio?

This episode covers important developments in healthcare, including updates on COVID. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.

How can healthcare professionals benefit from this information?

Healthcare professionals can stay informed about the latest developments in COVID and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.

Where can I find more information about COVID?

For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.

Dr. Eugene Chan is a physician-inventor. He is currently Chairman, Co-Founder of Abpro, CEO of rHEALTH, and President, CSO of DNA Medicine Institute, a medical innovation laboratory. He has been honored as Esquire magazine’s Best and Brightest, one of MIT Technology Review’s Top 100 Innovators, and an XPRIZE winner. His work has contributed to the birth of next-generation sequencing, health monitoring in remote environments, and therapeutics. Dr. Chan holds over 60 patents and publications, with work funded by the NIH, NASA, and USAF. Dr. Chan received an A.B. in Biochemical Sciences from Harvard College summa cum laude in 1996, received an M.D. from Harvard Medical School with honors in 2007, and trained in medicine at the Brigham and Women’s Hospital.

Last updated: January 24, 2023

Medical Disclaimer

The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.